UCBJY实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 03:45):

Stats
今日成交量	36 599.00
平均成交量	12 870.00
市值	25.23B
Last Dividend	$0.726 ( 2023-05-01 )
Next Dividend	$0 ( N/A )
P/E	70.72
ATR14	$0.189 (0.28%)

UCB SA 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

UCB SA 财务报表

Annual	2023
营收:	$5.25B
毛利润:	$3.55B (67.50 %)
EPS:	$1.810

FY	2023
营收:	$5.25B
毛利润:	$3.55B (67.50 %)
EPS:	$1.810

FY	2022
营收:	$5.52B
毛利润:	$3.84B (69.64 %)
EPS:	$2.20

FY	2021
营收:	$5.78B
毛利润:	$4.34B (75.11 %)
EPS:	$5.60

Financial Reports:

No articles found.

UCB SA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.726 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

UCB SA Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.90 - Stable (2.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.663	2013-05-02
Last Dividend	$0.726	2023-05-01
Next Dividend	$0	N/A
Payout Date	2023-05-18
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$7.46	--
Avg. Dividend % Per Year	0.00%	--
Score	3.23	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.90
Div. Directional Score	8.72	--

Next Divdend (Est)
(2025-03-31)

$0.745 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
RGPCF	Ex Dividend Junior	2023-09-01	Semi-Annually	0.00%
FBPI	Ex Dividend Knight	2023-08-30	Quarterly	0.00%
VTKLY	Ex Dividend Knight	2023-07-20	Semi-Annually	0.00%
LNVGY	Ex Dividend Knight	2023-07-26	Annually	0.00%
CKHGY	Ex Dividend Knight	2023-05-11	Annually	0.00%
SGPYY	Ex Dividend Knight	2023-06-01	Semi-Annually	0.00%
GMVHY	Ex Dividend Junior	2023-08-18	Semi-Annually	0.00%
AILLO	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
NACB	Ex Dividend Junior	2023-08-15	Quarterly	0.00%
CPKF	Ex Dividend Knight	2023-08-31	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0656	1.500	8.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0331	1.200	8.90	10.00	[0 - 0.3]
returnOnEquityTTM	0.0571	1.500	-0.477	-0.715	[0.1 - 1]
payoutRatioTTM	0.490	-1.000	5.10	-5.10	[0 - 1]
currentRatioTTM	1.317	0.800	8.42	6.73	[1 - 3]
quickRatioTTM	0.839	0.800	9.77	7.81	[0.8 - 2.5]
cashRatioTTM	0.329	1.500	9.28	10.00	[0.2 - 2]
debtRatioTTM	0.196	-1.500	6.74	-10.00	[0 - 0.6]
interestCoverageTTM	4.50	1.000	9.45	9.45	[3 - 30]
operatingCashFlowPerShareTTM	5.26	2.00	8.25	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.96	2.00	8.52	10.00	[0 - 20]
debtEquityRatioTTM	0.338	-1.500	8.65	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.648	1.000	2.54	2.54	[0.2 - 0.8]
operatingProfitMarginTTM	0.120	1.000	9.59	9.59	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.328	1.000	9.29	9.29	[0.2 - 2]
assetTurnoverTTM	0.505	0.800	9.97	7.97	[0.5 - 2]
Total Score				12.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	22.86	1.000	7.79	0	[1 - 100]
returnOnEquityTTM	0.0571	2.50	-0.306	-0.715	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
dividendYielPercentageTTM	2.34	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.26	2.00	8.25	10.00	[0 - 30]
payoutRatioTTM	0.490	1.500	5.10	-5.10	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.127	1.000	9.32	0	[0.1 - 0.5]
Total Score				4.90

UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.